Laura Brege, Director at ACADIA PHARMACEUTICALS INC (ACAD), sold 44,117 shares at $23.41 ($1.0M) on 2013-12-10, disclosed to the SEC on 2013-12-12.
Scheduled sale ($1.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| PCRX | BUY | 2024-08-19 | $13K | — | Filing → |
| ACAD | SELL | 2023-06-14 | $112K | — | Filing → |
| PCRX | SELL | 2023-06-07 | $23K | — | Filing → |